Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DECB0K3)

• DME Name: Cytochrome P450 2D6 (CYP2D6)
• Synonyms: Cytochrome P450 family 2 subfamily D member 6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; CYP2D6; CYP2DL1; CYPIID6
• Gene Name: CYP2D6
• UniProt ID: CP2D6_HUMAN
• INTEDE ID: DME0009
• Gene ID: 1565
• EC Number:
  EC: 1.14.14.1
  Oxidoreductase
  Oxygen paired donor oxidoreductase
  Flavin/flavoprotein donor oxidoreductase
  EC: 1.14.14.1
• Lineage:
  Species: Homo sapiens
  Kingdom: Metazoa
  Phylum: Chordata
  Class: Mammalia
  Order: Primates
  Family: Hominidae
  Genus: Homo
  Species: Homo sapiens
• Sequence:
  MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
  LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
  LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
  AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
  LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
  DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
  HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
  LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
  FAFLVSPSPYELCAVPR
• Function: This enzyme is involved in the metabolism of fatty acids, steroids and retinoids. It catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA). It also metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs). In addition, it catalyzes the hydroxylation of carbon-hydrogen bonds and metabolizes cholesterol toward 25- hydroxycholesterol. It catalyzes the oxidative transformations of all-trans retinol to all-trans retina and also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
• KEGG Pathway:
  Drug metabolism - cytochrome P450 (hsa00982)
  Endocrine resistance (hsa01522)
  Metabolism of xenobiotics by cytochrome P450 (hsa00980)
  Serotonergic synapse (hsa04726)
• Reactome Pathway:
  CYP2E1 reactions (R-HSA-211999)
  Fatty acids (R-HSA-211935)
  Miscellaneous substrates (R-HSA-211958)
  Xenobiotics (R-HSA-211981)
  Biosynthesis of maresin-like SPMs (R-HSA-9027307)

Molecular Interaction Atlas (MIA) of This DME

262 Approved Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[26]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[27]
Ajmaline	DMDJW5K	Atrial fibrillation	BC81.3	Approved	[28]
Almotriptan malate	DMFG5ST	Migraine	8A80	Approved	[29]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[30]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[31]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[32]
Amoxapine	DMKITQE	Major depressive disorder	6A70.3	Approved	[33]
Amphetamine	DMSZQAK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[34]
Amprenavir	DMLMXE0	Human immunodeficiency virus infection	1C62	Approved	[35]
Amsacrine	DMZKYIV	Acute lymphoblastic leukaemia	2A85	Approved	[36]
Anisodamine	DMW51AX	Central and peripheral nervous disease	8A04-8E7Z	Approved	[26]
Aprindine	DMBXWU8	Cardiac arrhythmias	BC9Z	Approved	[37]
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[38]
Aripiprazole	DM3NUMH	Erythropoietic porphyrias	5C58.12	Approved	[39]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[40]
Asenapine	DMSQZE2	Schizophrenia	6A20	Approved	[41]
Atenolol	DMNKG1Z	Hypertension	BA00-BA04	Approved	[26]
Atomoxetine	DM5L6HI	Attention deficit hyperactivity disorder	6A05.Z	Approved	[42]
Azelastine	DMXTMBJ	Allergic conjunctivitis	9A60.02	Approved	[43]
Benzatropine	DMF7EXL	Psychomotor agitation	MB23.M	Approved	[44]
Benzyl alcohol	DMBVYDI	Head and body lice	1G00.0	Approved	[45]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[46]
Betaxolol	DM6EUL5	Hypertension	BA00-BA04	Approved	[47]
Bevantolol	DMZFICR	Hypertension	BA00-BA04	Approved	[26]
Bisoprolol	DM3UZ95	Hypertension	BA00-BA04	Approved	[48]
Bopindolol	DMIFYLX	Hypertension	BA00-BA04	Approved	[26]
Bortezomib	DMNO38U	Mantle cell lymphoma	2A85.5	Approved	[49]
Buflomedil	DMG1OPF	Peripheral vascular disease	BD4Z	Approved	[50]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[51]
Buprenorphine	DMPRI8G	Pain	MG30-MG3Z	Approved	[52]
Bupropion	DM5PCS7	Smoking dependence	6C4A.2	Approved	[53]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[54]
Caffeine	DMKBJWP	Orthostatic hypotension	BA21	Approved	[55]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[56]
Capsaicin	DMGMF6V	Neuropathic pain	8E43.0	Approved	[57]
Captopril	DM458UM	Hypertension	BA00-BA04	Approved	[28]
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[58]
Carteolol	DMFMDOB	Glaucoma/ocular hypertension	9C61	Approved	[59]
Carvedilol	DMHTEAO	Congestive heart failure	BD10	Approved	[49]
Celecoxib	DM6LOQU	Rheumatoid arthritis	FA20	Approved	[60]
Cephalexin	DMD5JU8	Bacterial infection	1A00-1C4Z	Approved	[61]
Cevimeline	DMWSMND	Sjogren syndrome	4A43.20	Approved	[62]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[63]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[64]
Chlorpromazine	DMBGZI3	Schizophrenia	6A20	Approved	[65]
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[66]
Ciclesonide	DM2NA4K	Asthma	CA23	Approved	[67]
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[68]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[69]
Cinnarizine	DM7U5QJ	Vertigo meniere disease	AB31.0	Approved	[49]
Citalopram	DM2G9AE	Depression	6A70-6A7Z	Approved	[70]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[71]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[72]
Clomifene	DMKI7RB	Female infertility	GA31.Z	Approved	[73]
Clonidine	DM6RZ9Q	Hypertension	BA00-BA04	Approved	[74]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[75]
Cobicistat	DM6L4H2	Human immunodeficiency virus infection	1C62	Approved	[76]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[77]
Codeine	DMJX6ZG	Pain	MG30-MG3Z	Approved	[78]
Cyclobenzaprine	DM1YBRM	Depression	6A70-6A7Z	Approved	[79]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[80]
Dapagliflozin	DM28UJG	Type-2 diabetes	5A11	Approved	[81]
Darifenacin	DMWXLYZ	Overactive bladder	GC50.0	Approved	[82]
Debrisoquin	DMC50ME	Hypertension	BA00-BA04	Approved	[83]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[84]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[85]
Desvenalfaxine succinate	DMJE6KO	Fibromyalgia	MG30.01	Approved	[86]
Deutetrabenazine	DMUPFLI	Huntington disease	8A01.10	Approved	[87]
Dexchlorpheniramine maleate	DMA8DPN	Rhinitis	FA20	Approved	[64]
Dextroamphetamine	DMMIHVP	Attention deficit hyperactivity disorder	6A05.Z	Approved	[34]
Dextromethorphan	DMUDJZM	Cough	MD12	Approved	[78]
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[88]
Diltiazem	DMAI7ZV	Hypertension	BA00-BA04	Approved	[89]
Diphenhydramine	DMKQTBA	Meniere disease	AB31.0	Approved	[90]
Dolasetron	DMMG26Z	Nausea	MD90	Approved	[91]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[92]
Donepezil	DMIYG7Z	Alzheimer disease	8A20	Approved	[93]
Dopamine	DMPGUCF	Parkinson disease	8A00.0	Approved	[94]
Doxazosin	DM9PLRH	Hypertension	BA00-BA04	Approved	[95]
Doxepin	DMPI98T	Depression	6A70-6A7Z	Approved	[96]
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[97]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[98]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[99]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[99]
Eletriptan	DMW649X	Migraine	8A80	Approved	[100]
Eliglustat tartrate	DMSRZAO	Metabolic disorder	5C50-5D2Z	Approved	[101]
Emetine	DMCT2YF	Hepatitis virus infection	1E50-1E51	Approved	[102]
Epinastine	DMX0K3Q	Allergic conjunctivitis	9A60.02	Approved	[103]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[104]
Escitalopram	DMFK9HG	Major depressive disorder	6A70.3	Approved	[105]
Esmolol	DM51TYR	Acute supraventricular tachycardia	BC81	Approved	[26]
Fesoterodine fumarate	DM13495	Overactive bladder	GC50.0	Approved	[106]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[107]
Flunarizine	DMZU5JP	Migraine	8A80	Approved	[49]
Fluoxetine	DM3PD2C	Depression	6A70-6A7Z	Approved	[108]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[75]
Fluvastatin	DM4MDJY	Hypercholesterolaemia	5C80.0	Approved	[109]
Formoterol	DMSOURV	Asthma	CA23	Approved	[38]
Fusidic acid	DMWVCF3	Bacterial infection	1A00-1C4Z	Approved	[110]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[111]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[112]
Granisetron	DMIUW25	Nausea and vomiting	MD90	Approved	[113]
Halofantrine	DMOMK1V	Malaria	1F40-1F45	Approved	[63]
Haloperidol	DM96SE0	Schizophrenia	6A20	Approved	[65]
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[28]
Hydrocodone bitartrate	DMIAPBE	Neuropathic pain	8E43.0	Approved	[114]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[115]
Hydromorphone	DMHP21E	Pain	MG30-MG3Z	Approved	[116]
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[117]
Idarubicin	DMM0XGL	Acute myeloid leukaemia	2A60	Approved	[118]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[119]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[120]
Incruse ellipta	DM32GSJ	Chronic obstructive pulmonary disease	CA22	Approved	[121]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[122]
Ipecac	DMLZTP9	Poison intoxication	NE6Z	Approved	[123]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[124]
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[125]
Levobetaxolol	DMSREPX	Chronic open-angle glaucoma	9C61.0	Approved	[26]
Levobunolol	DMTNFCQ	Open-angle glaucoma	9C61	Approved	[26]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[126]
Levomepromazine	DMIKFEL	Bipolar disorder	6A60	Approved	[127]
Levomilnacipran	DMV26S8	Fibromyalgia	MG30.01	Approved	[]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[128]
Lisdexamfetamine	DM6W8V5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[129]
Lisuride	DMCME17	Parkinson disease	8A00.0	Approved	[130]
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[131]
Loperamide	DMOJZQ9	Diarrhea	ME05.1	Approved	[132]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[133]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[134]
Loxapine	DM8AI9U	Schizophrenia	6A20	Approved	[135]
Luvox	DMJKROX	Anxiety disorder	6B00-6B0Z	Approved	[136]
Maprotiline	DMPWB7T	Major depressive disorder	6A70.3	Approved	[137]
Meclizine	DMS7T13	Dizziness	MB48	Approved	[138]
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[139]
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[140]
Mepindolol	DMUDWP9	Angina pectoris	BA40	Approved	[26]
Mequitazine	DMAFBCY	Allergic rhinitis	CA08.0	Approved	[141]
Mesoridazine	DM2ZGAN	Schizophrenia	6A20	Approved	[142]
Methadone	DMTW6IU	Dry cough	MD12	Approved	[143]
Methamphetamine	DMPM4SK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[144]
Methamphetamine hydrochloride	DMO2JBC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[144]
Methoxyflurane	DML0RAE	Anaesthesia	9A78.6	Approved	[145]
Methyldopa	DM5I621	Hypertension	BA00-BA04	Approved	[146]
Methyprylon	DMBW7VH	Insomnia	7A00-7A0Z	Approved	[147]
Metipranolol	DMJMVKI	Open-angle glaucoma	9C61	Approved	[26]
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[148]
Metoprolol	DMOJ0V6	Hypertension	BA00-BA04	Approved	[149]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[150]
Mianserin	DMVKA4O	Depression	6A70-6A7Z	Approved	[151]
Midodrine	DME2PY5	Orthostatic hypotension	BA21	Approved	[152]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[153]
Mirabegron	DMS1GYT	Overactive bladder	GC50.0	Approved	[154]
Mirtazapine	DML53ZJ	Depression	6A70-6A7Z	Approved	[155]
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[156]
Morphine	DMRMS0L	Chronic pain	MG30	Approved	[157]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[158]
Nebivolol	DM7F1PA	Hypertension	BA00-BA04	Approved	[159]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[160]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[161]
Nicardipine	DMCDYW7	High blood pressure	BA00	Approved	[162]
Nicergoline	DMBCM8L	Brain ischaemia	8B1Z	Approved	[163]
Nicotine	DMWX5CO	Nicotine dependence	6C4A.2	Approved	[164]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[165]
Nitrofurazone	DMSM2KE	Skin burns	ME65.0	Approved	[166]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[167]
Olanzapine	DMPFN6Y	Schizophrenia	6A20	Approved	[168]
Oliceridine	DM6MDCF	Acute pain	MG31	Approved	[169]
Ondansetron	DMOTQ1I	Chemotherapy-induced nausea	MD90	Approved	[170]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[171]
Opipramol	DMPUOXF	Anxiety disorder	6B00-6B0Z	Approved	[28]
Oxamniquine	DM2QDX1	Schistosomiasis	1F86	Approved	[172]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[173]
Oxprenolol	DM51OQW	Hypertension	BA00-BA04	Approved	[26]
Oxymorphone	DM65AGJ	Pain	MG30-MG3Z	Approved	[174]
Paliperidone	DM7NPJS	Schizophrenia	6A20	Approved	[175]
Palonosetron	DMBHMOX	Nausea	MD90	Approved	[170]
Paroxetine	DM5PVQE	Depression	6A70-6A7Z	Approved	[176]
Pazopanib	DMF57DM	Renal cell carcinoma	2C90	Approved	[177]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[26]
Pentamidine	DMHZJCG	Fungal infection	1F29-1F2F	Approved	[178]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[179]
Perhexiline	DMINO7Z	Angina pectoris	BA40	Approved	[180]
Perospirone	DMVHJLX	Psychotic disorder	6A20-6A25	Approved	[181]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[65]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[182]
Piperazine	DMTY9LU	Ascariasis	1F62	Approved	[183]
Pipotiazine	DMC68DF	Schizophrenia	6A20	Approved	[184]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[185]
Practolol	DMGLZ26	Cardiac arrhythmias	BC9Z	Approved	[26]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[186]
Prochlorperazine	DM53SRA	Nausea	MD90	Approved	[187]
Progesterone	DMUY35B	Premature labour	JB00	Approved	[188]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[75]
Promethazine	DM6I5GR	Nausea	MD90	Approved	[152]
Propafenone	DMPIBJK	Tachyarrhythmias	BC71	Approved	[189]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[190]
Propranolol	DM79NTF	Migraine	8A80	Approved	[191]
Pyrantel	DMG2X3E	Worm infection	1F90.Z	Approved	[178]
Quetiapine	DM1N62C	Schizophrenia	6A20	Approved	[192]
Quinidine	DMLPICK	Tachyarrhythmias	BC71	Approved	[193]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[194]
Ranitidine	DM0GUSX	Peptic ulcer	DA61	Approved	[195]
Ranolazine	DM0C9IL	Chronic/stable angina	BA40.1	Approved	[196]
Revefenacin	DMMP5SI	Chronic obstructive pulmonary disease	CA22	Approved	[197]
Rifampicin	DM5DSFZ	Osteoporosis	FB83.0	Approved	[198]
Risperidone	DMN6DXL	Schizophrenia	6A20	Approved	[199]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[200]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[28]
Rucaparib	DM9PVX8	Ovarian cancer	2C73	Approved	[]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[122]
Selegiline hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[201]
Sertraline	DM0FB1J	Depression	6A70-6A7Z	Approved	[202]
Sildenafil citrate	DMSWJ5X	Erectile dysfunction	HA01.1	Approved	[49]
Simvastatin	DM30SGU	Hypercholesterolaemia	5C80.0	Approved	[203]
Solifenacin	DMG592Q	Overactive bladder	GC50.0	Approved	[204]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[26]
Tafenoquine	DM1XT4N	Malaria	1F40-1F45	Approved	[205]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[206]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[207]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[208]
Tegaserod	DM3XYD1	Irritable bowel syndrome	DD91.0	Approved	[209]
Tertatolol	DM2L3D5	Hypertension	BA00-BA04	Approved	[26]
Tetrabenazine	DMYWQ0O	Huntington disease	8A01.10	Approved	[210]
Theophylline	DMRJFN9	Chronic obstructive pulmonary disease	CA22	Approved	[211]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[142]
Ticlopidine	DMO946V	Stroke	8B20	Approved	[212]
Timolol	DM3NXRU	High blood pressure	BA00	Approved	[213]
Tipranavir	DM8HJX6	Human immunodeficiency virus infection	1C62	Approved	[214]
Tolperisone	DMA2GHJ	Muscle spasm	MB47.3	Approved	[215]
Tolterodine	DMSHPW8	Overactive bladder	GC50.0	Approved	[216]
Trabectedin	DMG3Y89	Solid tumour/cancer	2A00-2F9Z	Approved	[217]
Tramadol	DMRQD04	Pain	MG30-MG3Z	Approved	[218]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[219]
Triclabendazole	DMPWGBR	Helminth infection	1F90.0	Approved	[220]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[221]
Tropisetron	DMNSJ7V	Fibromyalgia	MG30.01	Approved	[170]
Upadacitinib	DM8T2OI	Rheumatoid arthritis	FA20	Approved	[222]
Venlafaxine	DMR6QH0	Depression	6A70-6A7Z	Approved	[223]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[224]
Vinblastine	DM5TVS3	Solid tumour/cancer	2A00-2F9Z	Approved	[97]
Vincamine	DMK1ZOR	Cerebrovascular disease	8B2Z	Approved	[225]
Vinorelbine	DMVXFYE	Solid tumour/cancer	2A00-2F9Z	Approved	[97]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[226]
Yohimbine	DMJCP1Y	Erectile dysfunction	HA01.1	Approved	[227]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[228]
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[229]
Zotepine	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[230]
Zuclopenthixol	DMKYD5N	Schizophrenia	6A20	Approved	[231]
Aminophenazone	DMY2AH1	Anaesthesia	9A78.6	Phase 4	[232]
Arotinolol	DML1VXW	Essential tremor or related tremors	8A04.1	Phase 4	[26]
Benzethonium	DMHKZX1	Staphylococcus infection	1B5Y	Phase 4	[44]
Celiprolol	DMYTGW0	Essential hypertension	BA00	Phase 4	[26]
Chlorphenamine	DM6C4YJ	Allergy	4A80-4A85	Phase 4	[64]
Cibenzoline	DMBG0N4	Atrial fibrillation	BC81.3	Phase 4	[233]
Dapoxetine	DMV6KFY	Premature ejaculation	HA03.0Z	Phase 4	[234]
Dihydrocodeine	DMB0FWL	Cancer related pain	MG30	Phase 4	[235]
Esmirtazapine	DMKEGI3	Depression	6A70-6A7Z	Phase 4	[236]
Guanoxan	DMLYXBF	Essential hypertension	BA00	Phase 4	[28]
Indenolol	DM2R496	Cardiac arrhythmias	BC9Z	Phase 4	[26]
Vonoprazan	DMCOJPS	Gastro-oesophageal reflux	DA22	Phase 4	[237]

32 Clinical Trial Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Azimilide	DMUIBV8	Atrial fibrillation	BC81.3	Phase 3	[238]
Bicifadine	DM42GP9	Chronic low back pain	MG30.02	Phase 3	[239]
FT-0710230	DMF4I1V	Opioid dependence	6C43.2Z	Phase 3	[240]
Iclaprim	DM7YNV9	Bacterial infection	1A00-1C4Z	Phase 3	[241]
Karenitecin	DMCRGY4	Lung cancer	2C25.0	Phase 3	[242]
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[243]
Muraglitazar	DMG3NFZ	N. A.	N. A.	Phase 3	[244]
Nabiximols	DMHKJ5I	Cancer related pain	MG30	Phase 3	[56]
NBI-98854	DMVO1C0	Movement disorder	8A07-8A0Z	Phase 3	[245]
Netupitant	DMEKAYI	Chemotherapy-induced nausea	MD90	Phase 3	[246]
Olodaterol/tiotropium bromide	DM1FBZ7	Chronic obstructive pulmonary disease	CA22	Phase 3	[247]
ONO-1101	DMU86DM	Atrial fibrillation	BC81.3	Phase 3	[26]
Vernakalant	DMOQ81Y	Atrial fibrillation	BC81.3	Phase 3	[248]
Bucindolol	DMV52CP	Atrial fibrillation	BC81.3	Phase 2/3	[26]
Fexinidazole	DMOYE70	Trypanosomiasis	1D51-1F53	Phase 2/3	[249]
Pactimibe	DM0NZDT	Arteriosclerosis	BD40	Phase 2/3	[250]
BCP-13498	DM2BO9W	Anaesthesia	9A78.6	Phase 2	[251]
BMS 650032	DMQI43G	Hepatitis C virus infection	1E51.1	Phase 2	[252]
CP-122721	DMSWLM5	Major depressive disorder	6A70.3	Phase 2	[253]
Ferroquine	DMICMXE	Malaria	1F40-1F45	Phase 2	[254]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[255]
LY2603618	DMCXRZF	Pancreatic cancer	2C10	Phase 2	[256]
Prajmaline	DMIVMR3	Atherosclerosis	BD40	Phase 2	[257]
Roxatidine	DMIZMYQ	Gastro-oesophageal reflux	DA22	Phase 2	[258]
Sitamaquine	DMY3JWO	Infectious disease	1A00-CA43.1	Phase 2	[259]
SQ-109	DMWK9BX	Bacterial infection	1A00-1C4Z	Phase 2	[260]
Sun13834	DMPK34E	Gram-positive bacterial infection	1B74-1G40	Phase 2	[28]
H3B-6545	DMIFCY2	Breast cancer	2C60-2C65	Phase 1/2	[261]
ABT-333	DM7TOWX	Hepatitis C virus infection	1E51.1	Phase 1	[262]
ITX-5061	DM702MU	Human immunodeficiency virus-1 infection	1C62	Phase 1	[263]
NSC-172130	DM6093Y	Depression	6A70-6A7Z	Phase 1	[264]
Salvinorin A	DMJ3HQY	Cerebral vasospasm	BA85.Z	Phase 1	[265]

23 Discontinued Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alprenolol	DMYJ8Z3	Hypertension	BA00-BA04	Withdrawn from market	[127]
Astemizole	DM2HN6Q	Allergic rhinitis	CA08.0	Withdrawn from market	[266]
Dexfenfluramine	DMJ7YDS	Obesity	5B81	Withdrawn from market	[267]
Encainide	DMK0GHV	Heart arrhythmia	BC65	Withdrawn from market	[268]
Indoramin	DMNSJFD	Hypertension	BA00-BA04	Withdrawn from market	[28]
Phenacetin	DMRQAM0	Analgesia	MB40.8	Withdrawn from market	[269]
Phenformin	DMQ52JG	Diabetic complication	5A2Y	Withdrawn from market	[77]
Remoxipride	DMGQF3R	Schizophrenia	6A20	Withdrawn from market	[28]
Sertindole	DMMP65N	Schizophrenia	6A20	Withdrawn from market	[270]
Terfenadine	DM4KLPT	Allergy	4A80-4A85	Withdrawn from market	[103]
Epanolol	DML1Y49	Angina pectoris	BA40	Discontinued in Preregistration	[26]
Etilevodopa	DMF93U1	Parkinson disease	8A00.0	Discontinued in Phase 3	[271]
Sabeluzole	DMSW051	Cerebrovascular ischaemia	8B1Z	Discontinued in Phase 3	[272]
Octopamine	DMLQVTJ	Thrombosis	DB61-GB90	Discontinued in Phase 2a	[273]
Benzydamine	DMEQL9U	Chemotherapy or radiotherapy-induced mucositis	DA42-DA60	Discontinued in Phase 2	[274]
BMS-181101	DMT4VSE	Mood disorder	6A60-6E23	Discontinued in Phase 2	[275]
Brofaromine	DMTEQ0G	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 2	[276]
Ezlopitant	DMTUPZ2	Irritable bowel syndrome	DD91.0	Discontinued in Phase 2	[277]
MCPP	DMIG5W8	Mood disorder	6A60-6E23	Discontinued in Phase 2	[278]
Nemifitide	DM6VP9U	Major depressive disorder	6A70.3	Discontinued in Phase 2	[279]
Tesmilifene	DMPB36I	Breast cancer	2C60-2C65	Discontinued in Phase 2	[280]
VR-776	DMFQWNI	Premature ejaculation	HA03.0Z	Discontinued in Phase 1	[281]
Gepirone	DMGX5Q0	Depression	6A70-6A7Z	Terminated	[283]

1 Preclinical Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oxycodone hydrochloride	DMCA7LN	Chronic pain	MG30	Application submitted	[282]

16 Investigative Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
5-MEO-DMT	DMG0EL7	Discovery agent	N.A.	Investigative	[284]
Befunolol	DMV15JC	Glaucoma/ocular hypertension	9C61	Investigative	[26]
Beta-methoxyamphetamine	DMA9CSG	Discovery agent	N.A.	Investigative	[285]
Bufuralol	DMJSC07	Cardiac arrhythmias	BC9Z	Investigative	[286]
Bupranolol	DMUT9IQ	Tachyarrhythmias	BC71	Investigative	[28]
Butyrfentanyl	DM9X2FV	Anaesthesia	9A78.6	Investigative	[287]
Chloroxylenol	DMM75WZ	Pseudomonas infection	1B92	Investigative	[28]
Cloranolol	DMH7GKB	Discovery agent	N.A.	Investigative	[26]
Ethylmorphine	DM0YROF	Discovery agent	N.A.	Investigative	[288]
Etilamfetamine	DMR9YL6	Pulmonary hypertension	BB01	Investigative	[34]
Lorpiprazole	DMK5J9M	Anxiety disorder	6B00-6B0Z	Investigative	[289]
Methoxyphenamine	DMN8HRU	Chronic obstructive pulmonary disease	CA22	Investigative	[290]
Methylenedioxymethamphetamine	DMYVU47	Discovery agent	N.A.	Investigative	[291]
Phenazone	DMCE985	Discovery agent	N.A.	Investigative	[292]
Repinotan	DM47TSV	Discovery agent	N.A.	Investigative	[293]
Sparteine	DMWCIMG	Cardiac arrhythmias	BC9Z	Investigative	[144]

Molecular Expression Atlas (MEA) of This DME

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Acute myelocytic leukaemia	2B33.1	Bone marrow	2.68E-01	5.03E-03	2.52E-02
Alopecia	ED70	Skin from scalp	2.07E-01	-1.74E-02	-7.66E-02
Alzheimer's disease	8A20	Entorhinal cortex	7.30E-01	-1.91E-02	-1.41E-01
Ankylosing spondylitis	FA92.0	Pheripheral blood	7.53E-01	1.21E-03	1.45E-02
Aortic stenosis	BB70	Calcified aortic valve	5.67E-01	1.35E-01	2.39E-01
Apnea	7A40	Hyperplastic tonsil	1.31E-01	-1.20E-01	-6.20E-01
Arthropathy	FA00-FA5Z	Peripheral blood	9.39E-02	3.35E-02	3.25E-01
Asthma	CA23	Nasal and bronchial airway	1.21E-04	-2.33E-01	-5.09E-01
Atopic dermatitis	EA80	Skin	3.35E-02	2.21E-02	1.60E-01
Autism	6A02	Whole blood	1.72E-01	1.22E-01	4.54E-01
Autoimmune uveitis	9A96	Peripheral monocyte	2.04E-03	-3.73E-01	-1.91E+00
Autosomal dominant monocytopenia	4B04	Whole blood	9.44E-01	-2.77E-02	-1.99E-01
Bacterial infection of gingival	1C1H	Gingival tissue	5.83E-01	-1.74E-02	-7.78E-02
Batten disease	5C56.1	Whole blood	1.03E-02	7.98E-02	1.16E+00
Behcet's disease	4A62	Peripheral blood	1.42E-01	6.96E-02	3.85E-01
Bipolar disorder	6A60-6A6Z	Prefrontal cortex	7.18E-01	-4.95E-02	-3.91E-01
Bladder cancer	2C94	Bladder tissue	6.53E-04	7.65E-01	2.65E+00
Breast cancer	2C60-2C6Z	Breast tissue	6.51E-02	-2.38E-02	-9.58E-02
Cardioembolic stroke	8B11.20	Whole blood	1.10E-01	-4.38E-02	-3.62E-01
Cervical cancer	2C77	Cervical tissue	5.95E-01	-2.05E-02	-1.41E-01
Childhood onset rheumatic disease	FA20.Z	Peripheral blood	7.46E-01	3.70E-02	1.18E-01
Chronic hepatitis C	1E51.1	Whole blood	1.31E-01	1.04E-01	8.98E-01
Chronic obstructive pulmonary disease	CA22	Lung tissue	8.01E-02	6.73E-02	3.36E-01
Chronic obstructive pulmonary disease	CA22	Small airway epithelium	2.91E-04	1.41E-01	6.14E-01
Chronic rhinosinusitis	CA0A	Sinus mucosa tissue	9.47E-01	-1.46E-01	-1.13E+00
Colon cancer	2B90	Colon tissue	5.39E-05	-5.40E-02	-2.65E-01
Coronary artery disease	BA80-BA8Z	Peripheral blood	8.21E-01	-3.72E-02	-1.96E-01
Diffuse large B-cell lymphoma	2A81	Tonsil tissue	7.88E-01	-1.28E-01	-5.96E-01
Endometriosis	GA10	Endometrium tissue	3.63E-01	8.24E-02	3.98E-01
Familial hypercholesterolemia	5C80.00	Peripheral blood	1.10E-01	-5.43E-02	-3.00E-01
Familial hypercholesterolemia	5C80.00	Whole blood	5.05E-04	-1.51E-01	-8.87E-01
Gastric cancer	2B72	Gastric tissue	1.16E-01	-1.10E-01	-1.38E+00
Glioblastopma	2A00.00	Nervous tissue	1.16E-22	-1.26E-01	-5.93E-01
Glioma	2A00.0Y-2A00.0Z	Brain stem tissue	5.73E-01	-1.42E-01	-5.35E-01
Glioma	2A00.0Y-2A00.0Z	White matter tissue	2.09E-09	-9.49E-01	-8.32E+00
Head and neck cancer	2D42	Head and neck tissue	1.14E-01	-7.61E-02	-3.24E-01
HIV-associated neurocognitive impairment	8A2Y-8A2Z	White matter tissue	1.56E-01	-6.08E-02	-4.60E-01
Huntington's disease	8A01.10	Whole blood	1.19E-01	1.42E-01	7.09E-01
Idiopathic pulmonary fibrosis	CB03.4	Lung tissue	2.89E-01	-1.95E-01	-9.15E-01
Immunodeficiency	4A00-4A20	Peripheral blood	5.53E-01	3.38E-02	2.92E-01
Influenza	1E30	Whole blood	7.29E-04	4.43E-01	1.04E+01
Interstitial cystitis	GC00.3	Bladder tissue	2.22E-01	6.96E-02	1.92E+00
Intracranial aneurysm	8B01.0	Intracranial artery	1.54E-01	8.93E-02	4.64E-01
Irritable bowel syndrome	DD91.0	Rectal colon tissue	8.20E-01	-1.63E-03	-1.13E-02
Ischemic stroke	8B11	Peripheral blood	2.41E-01	6.24E-02	6.02E-01
Juvenile idiopathic arthritis	FA24	Peripheral blood	6.87E-01	-3.81E-02	-1.61E-01
Lateral sclerosis	8B60.4	Skin	3.40E-01	1.04E-01	7.11E-01
Lateral sclerosis	8B60.4	Cervical spinal cord	7.43E-01	2.19E-03	1.72E-02
Liver cancer	2C12.0	Liver tissue	2.63E-04	-2.52E-01	-6.62E-01
Liver failure	DB99.7-DB99.8	Liver tissue	5.60E-02	-2.52E-01	-1.10E+00
Lung cancer	2C25	Lung tissue	1.76E-04	-4.73E-02	-2.39E-01
Lupus erythematosus	4A40	Whole blood	9.24E-03	-3.04E-01	-6.23E-01
Major depressive disorder	6A70-6A7Z	Hippocampus	5.64E-01	2.36E-02	1.75E-01
Major depressive disorder	6A70-6A7Z	Whole blood	2.65E-01	4.83E-03	2.84E-02
Melanoma	2C30	Skin	9.64E-02	-1.20E-01	-3.11E-01
Multiple myeloma	2A83.1	Peripheral blood	5.28E-01	-3.69E-02	-1.61E-01
Multiple myeloma	2A83.1	Bone marrow	9.35E-01	-5.39E-03	-5.20E-02
Multiple sclerosis	8A40	Plasmacytoid dendritic cells	7.95E-01	-7.47E-02	-2.45E-01
Myelodysplastic syndrome	2A36-2A3Z	Bone marrow	4.26E-01	5.09E-02	2.01E-01
Myelofibrosis	2A20.2	Whole blood	3.41E-01	-1.92E-02	-2.46E-01
Myocardial infarction	BA41-BA50	Peripheral blood	2.19E-02	3.12E-01	8.06E-01
Myopathy	8C70.6	Muscle tissue	2.32E-03	-2.71E-01	-1.58E+00
Neonatal sepsis	KA60	Whole blood	7.68E-02	-7.62E-02	-2.41E-01
Neuroectodermal tumour	2A00.11	Brain stem tissue	3.34E-01	-2.49E-01	-7.53E-01
Non-alcoholic fatty liver disease	DB92	Liver tissue	9.95E-01	-1.11E-01	-5.80E-01
Obesity related type 2 diabetes	5A11	Omental adipose tissue	8.74E-02	2.10E-01	1.13E+00
Olive pollen allergy	CA08.00	Peripheral blood	9.85E-01	-6.08E-02	-2.34E-01
Oral cancer	2B6E	Oral tissue	4.10E-11	-3.94E-01	-1.97E+00
Osteoarthritis	FA00-FA0Z	Synovial tissue	2.41E-01	-1.97E-01	-7.83E-01
Osteoporosis	FB83.1	Bone marrow	7.53E-04	4.13E-01	3.30E+00
Ovarian cancer	2C73	Ovarian tissue	1.02E-01	-3.26E-02	-1.33E-01
Pancreatic cancer	2C10	Pancreas	6.44E-02	-1.56E-01	-4.37E-01
Parkinson's disease	8A00.0	Substantia nigra tissue	8.70E-01	2.98E-02	1.22E-01
Pediatric respiratory syncytial virus infection	CA40.11	Peripheral blood	9.24E-04	-1.83E-01	-1.21E+00
Pituitary cancer	2D12	Pituitary tissue	4.79E-02	2.40E-01	6.54E-01
Pituitary gonadotrope tumour	2D12	Pituitary tissue	4.16E-02	1.69E-01	7.14E-01
Polycystic ovary syndrome	5A80.1	Vastus lateralis muscle	4.22E-01	-3.99E-02	-1.53E-01
Polycythemia vera	2A20.4	Whole blood	2.22E-02	-2.51E-02	-2.94E-01
Pompe disease	5C51.3	Biceps muscle	8.18E-01	-3.78E-02	-2.13E-01
Preterm birth	KA21.4Z	Myometrium	5.79E-01	-1.18E-01	-8.68E-01
Prostate cancer	2C82	Prostate	8.66E-01	-1.19E-01	-3.65E-01
Psoriasis	EA90	Skin	7.74E-01	-3.86E-02	-1.04E-01
Rectal cancer	2B92	Rectal colon tissue	4.98E-01	1.97E-02	2.59E-01
Renal cancer	2C90-2C91	Kidney	8.59E-01	-4.51E-02	-1.36E-01
Retinoblastoma	2D02.2	Uvea	3.21E-06	-4.93E-01	-6.09E+00
Rheumatoid arthritis	FA20	Synovial tissue	1.61E-03	-6.79E-01	-2.18E+00
Rhinovirus infection	CA42.1	Nasal epithelium tissue	6.00E-01	-7.71E-03	-5.19E-02
Schizophrenia	6A20	Prefrontal cortex	2.59E-01	6.29E-02	3.14E-01
Schizophrenia	6A20	Superior temporal cortex	4.84E-01	-8.38E-02	-8.46E-01
Scleroderma	4A42.Z	Whole blood	8.28E-02	8.85E-02	8.03E-01
Seizure	8A60-8A6Z	Whole blood	7.32E-01	7.56E-02	4.21E-01
Sensitive skin	EK0Z	Skin	7.28E-02	7.52E-02	6.09E-01
Sepsis with septic shock	1G41	Whole blood	9.79E-01	7.87E-02	2.63E-01
Shwachman-Diamond syndrome	3A70.0	Bone marrow	2.13E-01	4.85E-01	1.58E+00
Sickle cell disease	3A51.0-3A51.3	Peripheral blood	2.28E-01	2.43E-01	7.45E-01
Simpson golabi behmel syndrome	LD2C	Adipose tissue	7.86E-01	-5.48E-02	-4.55E-01
Sjogren's syndrome	4A43.2	Salivary gland tissue	8.44E-02	-5.80E-01	-1.74E+00
Skin cancer	2C30-2C3Z	Skin	5.37E-01	-3.80E-02	-1.16E-01
Thrombocythemia	3B63	Whole blood	6.76E-03	-1.19E-01	-1.54E+00
Thrombocytopenia	3B64	Whole blood	5.86E-01	3.72E-01	8.87E-01
Thyroid cancer	2D10	Thyroid	3.46E-07	2.36E-01	7.25E-01
Tibial muscular dystrophy	8C75	Muscle tissue	7.51E-09	-6.44E-01	-3.30E+00
Tuberous sclerosis complex	LD2D.2	Perituberal tissue	1.79E-01	8.11E-02	1.23E+00
Type 2 diabetes	5A11	Liver tissue	7.04E-01	-2.88E-01	-5.42E-01
Ureter cancer	2C92	Urothelium	5.68E-01	-3.39E-02	-1.30E-01
Uterine cancer	2C78	Endometrium tissue	3.27E-02	-6.33E-02	-2.52E-01
Vitiligo	ED63.0	Skin	4.77E-01	-2.23E-02	-1.96E-01

The Drug Therapeutic Target (DTT) Role of This DME

• DME DTT Name: Debrisoquine 4-hydroxylase (CYP2D6) DTT Info
• DME DTT Type: Successful

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glutethimide	DMGE0CW	Insomnia	7A00-7A0Z	Approved	[1], [2]

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoquine	DMR17YI	Malaria	1F40-1F45	Phase 1	[3]

45 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(2-hydroxy-3-phenoxypropyl)(propan-2-yl)amine	DMCHJL1	Discovery agent	N.A.	Investigative	[4]
(5-(pyridin-3-yl)furan-2-yl)methanamine	DMTC5VF	Discovery agent	N.A.	Investigative	[5]
(5-phenylfuran-2-yl)methanamine	DMORD8S	Discovery agent	N.A.	Investigative	[5]
(5-pyridin-3-yl-furan-2-yl)methanethiol	DMKC2BE	Discovery agent	N.A.	Investigative	[5]
1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one	DMPOAB7	Discovery agent	N.A.	Investigative	[6]
1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)	DMYZ548	Discovery agent	N.A.	Investigative	[7]
1-(4-Butoxy-phenyl)-1H-imidazole	DMOEGZV	Discovery agent	N.A.	Investigative	[8]
1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)	DMI479T	Discovery agent	N.A.	Investigative	[7]
1H-1,2,3-benzotriazol-1-amine	DM9KAI5	Discovery agent	N.A.	Investigative	[9]
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole	DMZVBPG	Discovery agent	N.A.	Investigative	[10]
2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine	DMUIVS9	Discovery agent	N.A.	Investigative	[8]
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol	DMUGAT8	Discovery agent	N.A.	Investigative	[11]
2-Hexyloxy-5-imidazol-1-yl-pyridine	DMKORTS	Discovery agent	N.A.	Investigative	[8]
2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	DM8A3NI	Discovery agent	N.A.	Investigative	[8]
3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine	DMN75RD	Discovery agent	N.A.	Investigative	[12]
3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	DMTLJMF	Discovery agent	N.A.	Investigative	[8]
4-(3-Pent-1-ynyl-benzyl)-1H-imidazole	DMEYV1B	Discovery agent	N.A.	Investigative	[13]
4-(3-Phenylethynyl-benzyl)-1H-imidazole	DMS4JVT	Discovery agent	N.A.	Investigative	[13]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide	DM0XDG6	Discovery agent	N.A.	Investigative	[14]
4-methylaminomethyl-7-methoxycoumarin	DMI1L6Q	Discovery agent	N.A.	Investigative	[15]
4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine	DM9UGO0	Discovery agent	N.A.	Investigative	[8]
4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine	DM7LV5A	Discovery agent	N.A.	Investigative	[8]
4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol	DMK4ICB	Discovery agent	N.A.	Investigative	[11]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	DM7ERYJ	Discovery agent	N.A.	Investigative	[11]
6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)	DMZHFWX	Discovery agent	N.A.	Investigative	[7]
Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine	DMQ98H5	Discovery agent	N.A.	Investigative	[16]
BMS-694153	DM8PA3U	Migraine	8A80	Investigative	[17]
BS 7581	DM1VF6H	Discovery agent	N.A.	Investigative	[18]
BS 7840	DMDYNBT	Discovery agent	N.A.	Investigative	[18]
BS 9106	DMQ2FDA	Discovery agent	N.A.	Investigative	[18]
Desethyl isoquine	DM47JFS	Discovery agent	N.A.	Investigative	[3]
DIHYDROCUBEBIN	DMZL7R6	Discovery agent	N.A.	Investigative	[19]
GB-12819	DM7B5HA	Discovery agent	N.A.	Investigative	[18]
GBR 12530	DMPOML4	Discovery agent	N.A.	Investigative	[18]
GBR-12289	DM2CUNP	Discovery agent	N.A.	Investigative	[18]
GNF-PF-2094	DM9J35R	Discovery agent	N.A.	Investigative	[20]
GNF-PF-4292	DMXWYMH	Discovery agent	N.A.	Investigative	[21]
GNF-PF-5411	DMZNAEQ	Discovery agent	N.A.	Investigative	[21]
Go-Y022	DMZNUAD	Discovery agent	N.A.	Investigative	[6]
ICI-199441	DMEWZ80	Discovery agent	N.A.	Investigative	[22]
Kaempferol-3-O-methyl ether	DMBG7X1	Discovery agent	N.A.	Investigative	[23]
Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine	DMQU9VD	Discovery agent	N.A.	Investigative	[16]
ML-3163	DM3S5UC	Discovery agent	N.A.	Investigative	[24]
Prodipine	DMGIF1L	Discovery agent	N.A.	Investigative	[21]
SB-210313	DM5EWQN	Discovery agent	N.A.	Investigative	[25]

References

• [1] A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78.
• [2] Neurosteroidogenesis in rat retinas. J Neurochem. 1994 Jul;63(1):86-96.
• [3] Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
• [4] A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3816-20.
• [5] Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001.
• [6] Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
• [7] 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
• [8] Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.
• [9] Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett. 2001 Dec 3;11(23):2993-5.
• [10] Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
• [11] New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
• [12] Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74.
• [13] 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists. J Med Chem. 2008 May 22;51(10):2944-53.
• [14] Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
• [15] Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. J Med Chem. 2010 Oct 14;53(19):7129-39.
• [16] 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39.
• [17] Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan... J Med Chem. 2008 Aug 28;51(16):4858-61.
• [18] Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30.
• [19] Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8.
• [20] Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines. Bioorg Med Chem Lett. 2010 Jan 1;20(1):228-31.
• [21] Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem. 1993 Apr 30;36(9):1136-45.
• [22] Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52.
• [23] Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities. J Nat Prod. 2004 Jul;67(7):1079-83.
• [24] Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
• [25] Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6.
• [26] Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
• [27] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [28] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [29] Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
• [30] An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
• [31] Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38.
• [32] Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
• [33] Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2.
• [34] Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
• [35] Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
• [36] Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res. 2000 Aug;6(8):3088-94.
• [37] Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. Biol Pharm Bull. 2006 Mar;29(3):517-21.
• [38] A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
• [39] Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
• [40] The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
• [41] Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
• [42] Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
• [43] Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Jul;27(7):792-7.
• [44] Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
• [45] Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos. 2001 Dec;29(12):1599-607.
• [46] Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity. Drug Metab Pharmacokinet. 2015 Aug;30(4):257-62.
• [47] Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43.
• [48] Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22.
• [49] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [50] DMW/ISSX 2000 Meeting. The Drug Metabolism Workshop/International Society for the Study of Xenobiotics. St. Andrews, Scotland, June 11-16, 2000. Abstracts. Drug Metab Rev. 2000;32 Suppl 1:1-136.
• [51] Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
• [52] Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull. 2005 Feb;28(2):212-6.
• [53] In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017 Jan 1;123:85-96.
• [54] Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
• [55] Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol. 1998 Jun;18(3):198-207.
• [56] Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
• [57] Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
• [58] Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
• [59] Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes. Xenobiotica. 1997 Nov;27(11):1121-9.
• [60] Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
• [61] Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004 Sep;60(7):473-80.
• [62] Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
• [63] Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
• [64] The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
• [65] Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
• [66] Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
• [67] Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
• [68] Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
• [69] Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
• [70] Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.
• [71] Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
• [72] Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
• [73] CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. 2008;23(2):101-5.
• [74] CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
• [75] Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
• [76] Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755-8.
• [77] Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8.
• [78] Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
• [79] Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
• [80] Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
• [81] Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
• [82] The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
• [83] Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins. 2005 May 1;59(2):339-46.
• [84] Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
• [85] Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73-8.
• [86] Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999 Apr;47(4):450-3.
• [87] FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
• [88] Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7.
• [89] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [90] Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
• [91] Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73.
• [92] Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
• [93] Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
• [94] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [95] Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
• [96] Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4.
• [97] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [98] Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci. 2018 Jan 1;111:13-19.
• [99] Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
• [100] Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
• [101] Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36.
• [102] Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
• [103] Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
• [104] Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
• [105] CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig. 2013 Sep;10(3):286-93.
• [106] Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
• [107] Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
• [108] (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
• [109] Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81.
• [110] The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005.
• [111] Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
• [112] Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
• [113] Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71.
• [114] The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
• [115] Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos. 2006 Dec;34(12):1958-65.
• [116] Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther. 1997 Mar;280(3):1374-82.
• [117] Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
• [118] In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
• [119] Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
• [120] QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6.
• [121] The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013 Dec;7(6):311-9.
• [122] Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
• [123] Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. doi: 10.1002/9781118105955.ch13
• [124] Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
• [125] Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992 Feb;32(2):176-83.
• [126] Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1372-7.
• [127] Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One. 2014 Nov 4;9(11):e90453.
• [128] Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
• [129] Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50.
• [130] Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
• [131] Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
• [132] Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
• [133] In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5.
• [134] Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
• [135] In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
• [136] Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.
• [137] Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
• [138] Meclizine metabolism and pharmacokinetics: formulation on its absorption. J Clin Pharmacol. 2012 Sep;52(9):1343-9.
• [139] CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6.
• [140] Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95.
• [141] Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
• [142] Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
• [143] Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
• [144] Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
• [145] Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
• [146] Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
• [147] Drugs and steatohepatitis. Semin Liver Dis. 2002;22(2):185-94.
• [148] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
• [149] The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715.
• [150] Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur J Clin Pharmacol. 2003 Sep;59(5-6):395-9.
• [151] Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy. Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104.
• [152] Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
• [153] Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem. 2003 Dec 1;11(24):5545-54.
• [154] Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
• [155] A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
• [156] Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7.
• [157] Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54.
• [158] Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43(4):267-78.
• [159] Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
• [160] Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
• [161] Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
• [162] Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
• [163] Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol. 1996 Dec;42(6):707-11.
• [164] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [165] Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
• [166] Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 2000 Aug;39(8):1008-16.
• [167] A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
• [168] [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7.
• [169] First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014 Mar;54(3):351-7.
• [170] Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
• [171] Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
• [172] Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol. 1995;48(1):35-8.
• [173] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [174] Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
• [175] Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302.
• [176] Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34.
• [177] Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54.
• [178] Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
• [179] Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
• [180] CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
• [181] Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
• [182] The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015 Jun;35(3):228-36.
• [183] Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31.
• [184] Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
• [185] Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
• [186] Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics. 1999 Dec;9(6):683-96.
• [187] Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72.
• [188] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [189] Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
• [190] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [191] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [192] A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
• [193] Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site. J Inorg Biochem. 2012 May;110:46-50.
• [194] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [195] Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
• [196] Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
• [197] A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017 Nov 2;18(1):182.
• [198] Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010 Apr;38(4):679-86.
• [199] Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005 Nov;78(5):520-8.
• [200] Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002 Sep-Oct;25(5):251-3.
• [201] Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease. Rinsho Shinkeigaku. 2005 Nov;45(11):895-8.
• [202] Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004 Jan-Feb;59(1):5-12.
• [203] Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
• [204] Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
• [205] Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99.
• [206] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [207] Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
• [208] Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
• [209] In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.
• [210] Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9.
• [211] Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
• [212] Effect of health foods on cytochrome P450-mediated drug metabolism. J Pharm Health Care Sci. 2017 May 10;3:14.
• [213] Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561.
• [214] A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
• [215] Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
• [216] Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos. 2010 Sep;38(9):1456-63.
• [217] In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
• [218] Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
• [219] Evaluating the role of drug metabolism and reactive intermediates in trazodone-induced cytotoxicity toward freshly-isolated rat hepatocytes. Drug Res (Stuttg). 2016 Nov;66(11):592-596.
• [220] FDA Label of Egaten. The 2020 official website of the U.S. Food and Drug Administration.
• [221] Galactorrhea during treatment with trimipramine. A case report. Pharmacopsychiatry. 2005 Nov;38(6):326-7.
• [222] Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
• [223] The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. Pharmacopsychiatry. 2019 Sep;52(5):222-231.
• [224] Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
• [225] Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
• [226] Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
• [227] Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008 Aug;20(8):891-9.
• [228] Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
• [229] Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002 Dec;23(9):361-7.
• [230] Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
• [231] Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84.
• [232] Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
• [233] Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
• [234] Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51.
• [235] The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106.
• [236] Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl). 2011 May;215(2):321-32.
• [237] In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
• [238] The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
• [239] In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007 Dec;35(12):2232-41.
• [240] Interpretation of opiate urine drug screens.
• [241] An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
• [242] Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
• [243] Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
• [244] Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
• [245] Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018 Apr;18(4):323-332.
• [246] Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
• [247] Tiotropium rromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPD. P T. 2016 Feb;41(2):97-102.
• [248] Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 Jan;49(1):17-29.
• [249] Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
• [250] Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos. 2008 Sep;36(9):1938-43.
• [251] Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000 Dec;28(12):1397-400.
• [252] Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions. Clin Pharmacokinet. 2015 Dec;54(12):1205-22.
• [253] In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
• [254] In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
• [255] Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology. 2004 Feb;145(2):699-705.
• [256] Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
• [257] Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr. 1985 Nov 15;63(22):1180-6.
• [258] Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
• [259] Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015 Jul;59(7):3864-9.
• [260] Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
• [261] Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
• [262] Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
• [263] ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
• [264] Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48.
• [265] Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7.
• [266] Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol. 2001 Feb;51(2):133-42.
• [267] Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. Pharmacogenetics. 1998 Oct;8(5):423-32.
• [268] Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000 Feb;38(2):111-80.
• [269] Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci. 1998 Dec;87(12):1502-7.
• [270] Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
• [271] Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
• [272] Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. Br J Clin Pharmacol. 2001 Feb;51(2):164-8.
• [273] Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 1998 Aug 28;249(3):838-43.
• [274] In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
• [275] Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. J Pharm Pharmacol. 1998 Mar;50(3):275-8.
• [276] Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor. Eur J Clin Pharmacol. 1993;45(3):265-9.
• [277] Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
• [278] Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Aug 15;855(2):127-33.
• [279] Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
• [280] N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol. 2000;45(4):298-304.
• [281] The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996 Jun;277(3):1659-64.
• [282] Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
• [283] Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs. 2004 Feb;7(2):143-50.
• [284] Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010 Oct;11(8):659-66.
• [285] Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 Jun 1;53(11):1605-12.
• [286] Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Mol Pharmacol. 2015 Apr;87(4):733-9.
• [287] Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Drug Test Anal. 2017 Jul;9(7):1085-1092.
• [288] A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. J Pharm Biomed Anal. 2002 Aug 22;30(1):113-24.
• [289] [Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression]. Psychiatr Pol. 2011 Jul-Aug;45(4):611-25.
• [290] Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. Xenobiotica. 1995 Sep;25(9):895-906.
• [291] Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr;26(2):137-44.
• [292] Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
• [293] Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach. Drug Metab Pharmacokinet. 2006 Feb;21(1):61-9.